BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16358965)

  • 1. Serum endostatin levels in patients with lung carcinoma.
    Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
    Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The value of serum endostatin level in early diagnosis of lung cancer].
    Xu AH; Yin YW; Chen FH
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(27):1916-8. PubMed ID: 17064531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer.
    Iizasa T; Chang H; Suzuki M; Otsuji M; Yokoi S; Chiyo M; Motohashi S; Yasufuku K; Sekine Y; Iyoda A; Shibuya K; Hiroshima K; Fujisawa T
    Clin Cancer Res; 2004 Aug; 10(16):5361-6. PubMed ID: 15328173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
    Qin J; Zhang PH; Qian XY; Kang SJ; Luo RC; Wang YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):930-2. PubMed ID: 18583230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
    Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
    Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
    Hu Y; Hu MM; Shi GL; Han Y; Li BL
    Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer].
    Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
    Pol Merkur Lekarski; 2007 Jun; 22(132):536-8. PubMed ID: 17874624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum beta-defensins concentrations in patients with lung cancer.
    Arimura Y; Ashitani J; Yanagi S; Tokojima M; Abe K; Mukae H; Nakazato M
    Anticancer Res; 2004; 24(6):4051-7. PubMed ID: 15736451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
    Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
    Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.